Us Renal Care Laredo South Dialysis is a medicare approved dialysis facility center in Laredo, Texas and it has 24 dialysis stations. It is located in Webb county at 4602 Bencha Road, Laredo, TX, 78041. You can reach out to the office of Us Renal Care Laredo South Dialysis at (956) 753-2121. This dialysis clinic is managed and/or owned by Us Renal Care, Inc.. Us Renal Care Laredo South Dialysis has the following ownership type - Profit. It was first certified by medicare in May, 2007. The medicare id for this facility is 672566 and it accepts patients under medicare ESRD program.
| Name | Us Renal Care Laredo South Dialysis |
|---|---|
| Location | 4602 Bencha Road, Laredo, Texas |
| No. of Dialysis Stations | 24 |
| Medicare ID | 672566 |
| Managed By | Us Renal Care, Inc. |
| Ownership Type | Profit |
| Late Shifts | No |
| 4602 Bencha Road, Laredo, Texas, 78041 | |
| (956) 753-2121 | |
News Archive
At the moment, doctors rely on biopsy analysis to determine the progression of eye cancer. However, researchers now believe that a new technology, bioluminescence imaging (BLI), will allow doctors to detect tumors earlier and quickly choose a method of treatment that doesn't necessarily involve eye surgery.
Labopharm Inc. today announced the closing of its previously announced underwritten public offering of 11,764,706 units. The units were sold at a price of US$1.70 per unit for gross proceeds of US$20 million. Net proceeds were US$18,150,000 after deducting underwriting discounts and commissions, and estimated offering expenses.
One of the fundamental traits of a tumor - how it avoids the immune system - might become its greatest vulnerability, according to researchers from the University of Southern California. Their findings, demonstrated in human breast and colorectal cancers, indicate that a technique for determining a tumor's "immune signature," could be useful for diagnosing and treating specific cancers.
The Pan American Health Organization (PAHO) and the University of Geneva have signed an agreement to increase and facilitate cooperation on emergency preparedness and disaster relief programs.
Want to know how healthy your heart is? Now there's an app for that. In a proof-of-concept clinical trial, engineers at Caltech, Huntington Medical Research Institute, and USC have demonstrated that the camera on your smartphone can noninvasively provide detailed information about your heart's health.
› Verified 8 days ago
| NPI Number | 1578613220 |
| Organization Name | Us Renal Care Laredo South Dialysis |
| Doing Business As | Usrc Laredo South Lp |
| Address | 4602 Bencha Dr Laredo, Texas, 78043 |
| Phone Number | (956) 668-8484 |
News Archive
At the moment, doctors rely on biopsy analysis to determine the progression of eye cancer. However, researchers now believe that a new technology, bioluminescence imaging (BLI), will allow doctors to detect tumors earlier and quickly choose a method of treatment that doesn't necessarily involve eye surgery.
Labopharm Inc. today announced the closing of its previously announced underwritten public offering of 11,764,706 units. The units were sold at a price of US$1.70 per unit for gross proceeds of US$20 million. Net proceeds were US$18,150,000 after deducting underwriting discounts and commissions, and estimated offering expenses.
One of the fundamental traits of a tumor - how it avoids the immune system - might become its greatest vulnerability, according to researchers from the University of Southern California. Their findings, demonstrated in human breast and colorectal cancers, indicate that a technique for determining a tumor's "immune signature," could be useful for diagnosing and treating specific cancers.
The Pan American Health Organization (PAHO) and the University of Geneva have signed an agreement to increase and facilitate cooperation on emergency preparedness and disaster relief programs.
Want to know how healthy your heart is? Now there's an app for that. In a proof-of-concept clinical trial, engineers at Caltech, Huntington Medical Research Institute, and USC have demonstrated that the camera on your smartphone can noninvasively provide detailed information about your heart's health.
› Verified 8 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that nephrologists always communicated and cared for them. | 75% | 67% |
| Patients who reported that nephrologists usually communicated and cared for them. | 12% | 15% |
| Patients who reported that nephrologists sometimes or never communicated and cared for them. | 13% | 18% |
| Patients who gave their nephrologists a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 62% | 60% |
| Patients who gave their nephrologists a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 25% | 26% |
| Patients who gave their nephrologists a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 13% | 14% |
News Archive
At the moment, doctors rely on biopsy analysis to determine the progression of eye cancer. However, researchers now believe that a new technology, bioluminescence imaging (BLI), will allow doctors to detect tumors earlier and quickly choose a method of treatment that doesn't necessarily involve eye surgery.
Labopharm Inc. today announced the closing of its previously announced underwritten public offering of 11,764,706 units. The units were sold at a price of US$1.70 per unit for gross proceeds of US$20 million. Net proceeds were US$18,150,000 after deducting underwriting discounts and commissions, and estimated offering expenses.
One of the fundamental traits of a tumor - how it avoids the immune system - might become its greatest vulnerability, according to researchers from the University of Southern California. Their findings, demonstrated in human breast and colorectal cancers, indicate that a technique for determining a tumor's "immune signature," could be useful for diagnosing and treating specific cancers.
The Pan American Health Organization (PAHO) and the University of Geneva have signed an agreement to increase and facilitate cooperation on emergency preparedness and disaster relief programs.
Want to know how healthy your heart is? Now there's an app for that. In a proof-of-concept clinical trial, engineers at Caltech, Huntington Medical Research Institute, and USC have demonstrated that the camera on your smartphone can noninvasively provide detailed information about your heart's health.
› Verified 8 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that dialysis center staff always communicated well, kept patients comfortable and pain-free as possible. | 66% | 62% |
| Patients who reported that dialysis center staff usually communicated, kept patients comfortable and pain-free as possible. | 16% | 20% |
| Patients who reported that dialysis center staff sometimes or never communicated, kept patients comfortable and pain-free. | 18% | 18% |
| Patients who gave their dialysis facility staff a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 67% | 62% |
| Patients who gave their dialysis facility staff a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 21% | 26% |
| Patients who gave their dialysis facility staff a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 12% | 12% |
News Archive
At the moment, doctors rely on biopsy analysis to determine the progression of eye cancer. However, researchers now believe that a new technology, bioluminescence imaging (BLI), will allow doctors to detect tumors earlier and quickly choose a method of treatment that doesn't necessarily involve eye surgery.
Labopharm Inc. today announced the closing of its previously announced underwritten public offering of 11,764,706 units. The units were sold at a price of US$1.70 per unit for gross proceeds of US$20 million. Net proceeds were US$18,150,000 after deducting underwriting discounts and commissions, and estimated offering expenses.
One of the fundamental traits of a tumor - how it avoids the immune system - might become its greatest vulnerability, according to researchers from the University of Southern California. Their findings, demonstrated in human breast and colorectal cancers, indicate that a technique for determining a tumor's "immune signature," could be useful for diagnosing and treating specific cancers.
The Pan American Health Organization (PAHO) and the University of Geneva have signed an agreement to increase and facilitate cooperation on emergency preparedness and disaster relief programs.
Want to know how healthy your heart is? Now there's an app for that. In a proof-of-concept clinical trial, engineers at Caltech, Huntington Medical Research Institute, and USC have demonstrated that the camera on your smartphone can noninvasively provide detailed information about your heart's health.
› Verified 8 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that 'YES', their nephrologists and dialysis center staff provided them the information they needed to take care of them. | 77% | 80% |
| Patients who reported that 'NO', their nephrologists and dialysis center staff does not provided them the information they needed to take care of them. | 23% | 20% |
| Patients who gave their dialysis center a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 80% | 68% |
| Patients who gave their dialysis center a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 10% | 20% |
| Patients who gave their dialysis center a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 10% | 12% |
News Archive
At the moment, doctors rely on biopsy analysis to determine the progression of eye cancer. However, researchers now believe that a new technology, bioluminescence imaging (BLI), will allow doctors to detect tumors earlier and quickly choose a method of treatment that doesn't necessarily involve eye surgery.
Labopharm Inc. today announced the closing of its previously announced underwritten public offering of 11,764,706 units. The units were sold at a price of US$1.70 per unit for gross proceeds of US$20 million. Net proceeds were US$18,150,000 after deducting underwriting discounts and commissions, and estimated offering expenses.
One of the fundamental traits of a tumor - how it avoids the immune system - might become its greatest vulnerability, according to researchers from the University of Southern California. Their findings, demonstrated in human breast and colorectal cancers, indicate that a technique for determining a tumor's "immune signature," could be useful for diagnosing and treating specific cancers.
The Pan American Health Organization (PAHO) and the University of Geneva have signed an agreement to increase and facilitate cooperation on emergency preparedness and disaster relief programs.
Want to know how healthy your heart is? Now there's an app for that. In a proof-of-concept clinical trial, engineers at Caltech, Huntington Medical Research Institute, and USC have demonstrated that the camera on your smartphone can noninvasively provide detailed information about your heart's health.
› Verified 8 days ago
| Dialysis patients with Hemoglobin data | 82 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 4 |
News Archive
At the moment, doctors rely on biopsy analysis to determine the progression of eye cancer. However, researchers now believe that a new technology, bioluminescence imaging (BLI), will allow doctors to detect tumors earlier and quickly choose a method of treatment that doesn't necessarily involve eye surgery.
Labopharm Inc. today announced the closing of its previously announced underwritten public offering of 11,764,706 units. The units were sold at a price of US$1.70 per unit for gross proceeds of US$20 million. Net proceeds were US$18,150,000 after deducting underwriting discounts and commissions, and estimated offering expenses.
One of the fundamental traits of a tumor - how it avoids the immune system - might become its greatest vulnerability, according to researchers from the University of Southern California. Their findings, demonstrated in human breast and colorectal cancers, indicate that a technique for determining a tumor's "immune signature," could be useful for diagnosing and treating specific cancers.
The Pan American Health Organization (PAHO) and the University of Geneva have signed an agreement to increase and facilitate cooperation on emergency preparedness and disaster relief programs.
Want to know how healthy your heart is? Now there's an app for that. In a proof-of-concept clinical trial, engineers at Caltech, Huntington Medical Research Institute, and USC have demonstrated that the camera on your smartphone can noninvasively provide detailed information about your heart's health.
› Verified 8 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 120 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 1106 |
| Percentage of adult patients getting regular hemodialysis at the center | 99 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
At the moment, doctors rely on biopsy analysis to determine the progression of eye cancer. However, researchers now believe that a new technology, bioluminescence imaging (BLI), will allow doctors to detect tumors earlier and quickly choose a method of treatment that doesn't necessarily involve eye surgery.
Labopharm Inc. today announced the closing of its previously announced underwritten public offering of 11,764,706 units. The units were sold at a price of US$1.70 per unit for gross proceeds of US$20 million. Net proceeds were US$18,150,000 after deducting underwriting discounts and commissions, and estimated offering expenses.
One of the fundamental traits of a tumor - how it avoids the immune system - might become its greatest vulnerability, according to researchers from the University of Southern California. Their findings, demonstrated in human breast and colorectal cancers, indicate that a technique for determining a tumor's "immune signature," could be useful for diagnosing and treating specific cancers.
The Pan American Health Organization (PAHO) and the University of Geneva have signed an agreement to increase and facilitate cooperation on emergency preparedness and disaster relief programs.
Want to know how healthy your heart is? Now there's an app for that. In a proof-of-concept clinical trial, engineers at Caltech, Huntington Medical Research Institute, and USC have demonstrated that the camera on your smartphone can noninvasively provide detailed information about your heart's health.
› Verified 8 days ago
| Adult patients getting regular peritoneal dialysis at the center | 13 |
| Adult patient months included in Kt/V greater than or equal to 1.7 | 115 |
| Percentage of adult patients getting regular peritoneal dialysis at the center | 68 |
| Percentage of pediatric patients getting regular peritoneal dialysis at the center |
News Archive
At the moment, doctors rely on biopsy analysis to determine the progression of eye cancer. However, researchers now believe that a new technology, bioluminescence imaging (BLI), will allow doctors to detect tumors earlier and quickly choose a method of treatment that doesn't necessarily involve eye surgery.
Labopharm Inc. today announced the closing of its previously announced underwritten public offering of 11,764,706 units. The units were sold at a price of US$1.70 per unit for gross proceeds of US$20 million. Net proceeds were US$18,150,000 after deducting underwriting discounts and commissions, and estimated offering expenses.
One of the fundamental traits of a tumor - how it avoids the immune system - might become its greatest vulnerability, according to researchers from the University of Southern California. Their findings, demonstrated in human breast and colorectal cancers, indicate that a technique for determining a tumor's "immune signature," could be useful for diagnosing and treating specific cancers.
The Pan American Health Organization (PAHO) and the University of Geneva have signed an agreement to increase and facilitate cooperation on emergency preparedness and disaster relief programs.
Want to know how healthy your heart is? Now there's an app for that. In a proof-of-concept clinical trial, engineers at Caltech, Huntington Medical Research Institute, and USC have demonstrated that the camera on your smartphone can noninvasively provide detailed information about your heart's health.
› Verified 8 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Us Renal Care Laredo South Dialysis with elevated calcium levels.
| Patients with hypercalcemia | 136 |
| Hypercalcemia patient months | 1268 |
| Hypercalcemia patients with serumcalcium greater than 10.2 mg | 1 |
| Patients with Serumphosphor | 137 |
| Patients with Serumphosphor less than 3.5 mg/dL | 8 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 23 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 27 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 28 |
| Patients with Serumphosphor greater than 7 mg/dL | 13 |
News Archive
At the moment, doctors rely on biopsy analysis to determine the progression of eye cancer. However, researchers now believe that a new technology, bioluminescence imaging (BLI), will allow doctors to detect tumors earlier and quickly choose a method of treatment that doesn't necessarily involve eye surgery.
Labopharm Inc. today announced the closing of its previously announced underwritten public offering of 11,764,706 units. The units were sold at a price of US$1.70 per unit for gross proceeds of US$20 million. Net proceeds were US$18,150,000 after deducting underwriting discounts and commissions, and estimated offering expenses.
One of the fundamental traits of a tumor - how it avoids the immune system - might become its greatest vulnerability, according to researchers from the University of Southern California. Their findings, demonstrated in human breast and colorectal cancers, indicate that a technique for determining a tumor's "immune signature," could be useful for diagnosing and treating specific cancers.
The Pan American Health Organization (PAHO) and the University of Geneva have signed an agreement to increase and facilitate cooperation on emergency preparedness and disaster relief programs.
Want to know how healthy your heart is? Now there's an app for that. In a proof-of-concept clinical trial, engineers at Caltech, Huntington Medical Research Institute, and USC have demonstrated that the camera on your smartphone can noninvasively provide detailed information about your heart's health.
› Verified 8 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 106 |
| Patient months included in arterial venous fistula and catheter summaries | 978 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 57 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 6 |
News Archive
At the moment, doctors rely on biopsy analysis to determine the progression of eye cancer. However, researchers now believe that a new technology, bioluminescence imaging (BLI), will allow doctors to detect tumors earlier and quickly choose a method of treatment that doesn't necessarily involve eye surgery.
Labopharm Inc. today announced the closing of its previously announced underwritten public offering of 11,764,706 units. The units were sold at a price of US$1.70 per unit for gross proceeds of US$20 million. Net proceeds were US$18,150,000 after deducting underwriting discounts and commissions, and estimated offering expenses.
One of the fundamental traits of a tumor - how it avoids the immune system - might become its greatest vulnerability, according to researchers from the University of Southern California. Their findings, demonstrated in human breast and colorectal cancers, indicate that a technique for determining a tumor's "immune signature," could be useful for diagnosing and treating specific cancers.
The Pan American Health Organization (PAHO) and the University of Geneva have signed an agreement to increase and facilitate cooperation on emergency preparedness and disaster relief programs.
Want to know how healthy your heart is? Now there's an app for that. In a proof-of-concept clinical trial, engineers at Caltech, Huntington Medical Research Institute, and USC have demonstrated that the camera on your smartphone can noninvasively provide detailed information about your heart's health.
› Verified 8 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 124 |
| Hospitalization Rate in facility | 137.3 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 226.7 |
| Hospitalization Rate: Lower Confidence Limit | 89.7 |
News Archive
At the moment, doctors rely on biopsy analysis to determine the progression of eye cancer. However, researchers now believe that a new technology, bioluminescence imaging (BLI), will allow doctors to detect tumors earlier and quickly choose a method of treatment that doesn't necessarily involve eye surgery.
Labopharm Inc. today announced the closing of its previously announced underwritten public offering of 11,764,706 units. The units were sold at a price of US$1.70 per unit for gross proceeds of US$20 million. Net proceeds were US$18,150,000 after deducting underwriting discounts and commissions, and estimated offering expenses.
One of the fundamental traits of a tumor - how it avoids the immune system - might become its greatest vulnerability, according to researchers from the University of Southern California. Their findings, demonstrated in human breast and colorectal cancers, indicate that a technique for determining a tumor's "immune signature," could be useful for diagnosing and treating specific cancers.
The Pan American Health Organization (PAHO) and the University of Geneva have signed an agreement to increase and facilitate cooperation on emergency preparedness and disaster relief programs.
Want to know how healthy your heart is? Now there's an app for that. In a proof-of-concept clinical trial, engineers at Caltech, Huntington Medical Research Institute, and USC have demonstrated that the camera on your smartphone can noninvasively provide detailed information about your heart's health.
› Verified 8 days ago
The rate of readmission show you whether patients who were being treated regularly at Us Renal Care Laredo South Dialysis were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 19.6 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 27.5 |
| Readmission Rate: Lower Confidence Limit | 13.3 |
News Archive
At the moment, doctors rely on biopsy analysis to determine the progression of eye cancer. However, researchers now believe that a new technology, bioluminescence imaging (BLI), will allow doctors to detect tumors earlier and quickly choose a method of treatment that doesn't necessarily involve eye surgery.
Labopharm Inc. today announced the closing of its previously announced underwritten public offering of 11,764,706 units. The units were sold at a price of US$1.70 per unit for gross proceeds of US$20 million. Net proceeds were US$18,150,000 after deducting underwriting discounts and commissions, and estimated offering expenses.
One of the fundamental traits of a tumor - how it avoids the immune system - might become its greatest vulnerability, according to researchers from the University of Southern California. Their findings, demonstrated in human breast and colorectal cancers, indicate that a technique for determining a tumor's "immune signature," could be useful for diagnosing and treating specific cancers.
The Pan American Health Organization (PAHO) and the University of Geneva have signed an agreement to increase and facilitate cooperation on emergency preparedness and disaster relief programs.
Want to know how healthy your heart is? Now there's an app for that. In a proof-of-concept clinical trial, engineers at Caltech, Huntington Medical Research Institute, and USC have demonstrated that the camera on your smartphone can noninvasively provide detailed information about your heart's health.
› Verified 8 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Us Renal Care Laredo South Dialysis get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | 1.1 (As Expected) |
| SIR: Upper Confidence Limit | 2.01 |
| SIR: Lower Confidence Limit | .54 |
News Archive
At the moment, doctors rely on biopsy analysis to determine the progression of eye cancer. However, researchers now believe that a new technology, bioluminescence imaging (BLI), will allow doctors to detect tumors earlier and quickly choose a method of treatment that doesn't necessarily involve eye surgery.
Labopharm Inc. today announced the closing of its previously announced underwritten public offering of 11,764,706 units. The units were sold at a price of US$1.70 per unit for gross proceeds of US$20 million. Net proceeds were US$18,150,000 after deducting underwriting discounts and commissions, and estimated offering expenses.
One of the fundamental traits of a tumor - how it avoids the immune system - might become its greatest vulnerability, according to researchers from the University of Southern California. Their findings, demonstrated in human breast and colorectal cancers, indicate that a technique for determining a tumor's "immune signature," could be useful for diagnosing and treating specific cancers.
The Pan American Health Organization (PAHO) and the University of Geneva have signed an agreement to increase and facilitate cooperation on emergency preparedness and disaster relief programs.
Want to know how healthy your heart is? Now there's an app for that. In a proof-of-concept clinical trial, engineers at Caltech, Huntington Medical Research Institute, and USC have demonstrated that the camera on your smartphone can noninvasively provide detailed information about your heart's health.
› Verified 8 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Us Renal Care Laredo South Dialysis's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 110 |
| Transfusion Rate in facility | 54.7 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 94.3 |
| Transfusion Rate: Lower Confidence Limit | 33.9 |
News Archive
At the moment, doctors rely on biopsy analysis to determine the progression of eye cancer. However, researchers now believe that a new technology, bioluminescence imaging (BLI), will allow doctors to detect tumors earlier and quickly choose a method of treatment that doesn't necessarily involve eye surgery.
Labopharm Inc. today announced the closing of its previously announced underwritten public offering of 11,764,706 units. The units were sold at a price of US$1.70 per unit for gross proceeds of US$20 million. Net proceeds were US$18,150,000 after deducting underwriting discounts and commissions, and estimated offering expenses.
One of the fundamental traits of a tumor - how it avoids the immune system - might become its greatest vulnerability, according to researchers from the University of Southern California. Their findings, demonstrated in human breast and colorectal cancers, indicate that a technique for determining a tumor's "immune signature," could be useful for diagnosing and treating specific cancers.
The Pan American Health Organization (PAHO) and the University of Geneva have signed an agreement to increase and facilitate cooperation on emergency preparedness and disaster relief programs.
Want to know how healthy your heart is? Now there's an app for that. In a proof-of-concept clinical trial, engineers at Caltech, Huntington Medical Research Institute, and USC have demonstrated that the camera on your smartphone can noninvasively provide detailed information about your heart's health.
› Verified 8 days ago
The rate of mortality show you whether patients who were being treated regularly at Us Renal Care Laredo South Dialysis lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 506 |
| Mortality Rate in facility | 13.1 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 17.8 |
| Mortality Rate: Lower Confidence Limit | 9.4 |
News Archive
At the moment, doctors rely on biopsy analysis to determine the progression of eye cancer. However, researchers now believe that a new technology, bioluminescence imaging (BLI), will allow doctors to detect tumors earlier and quickly choose a method of treatment that doesn't necessarily involve eye surgery.
Labopharm Inc. today announced the closing of its previously announced underwritten public offering of 11,764,706 units. The units were sold at a price of US$1.70 per unit for gross proceeds of US$20 million. Net proceeds were US$18,150,000 after deducting underwriting discounts and commissions, and estimated offering expenses.
One of the fundamental traits of a tumor - how it avoids the immune system - might become its greatest vulnerability, according to researchers from the University of Southern California. Their findings, demonstrated in human breast and colorectal cancers, indicate that a technique for determining a tumor's "immune signature," could be useful for diagnosing and treating specific cancers.
The Pan American Health Organization (PAHO) and the University of Geneva have signed an agreement to increase and facilitate cooperation on emergency preparedness and disaster relief programs.
Want to know how healthy your heart is? Now there's an app for that. In a proof-of-concept clinical trial, engineers at Caltech, Huntington Medical Research Institute, and USC have demonstrated that the camera on your smartphone can noninvasively provide detailed information about your heart's health.
› Verified 8 days ago
Satellite Healthcare North Laredo Location: 5501 Springfield Avenue, Laredo, Texas, 78041 Phone: (956) 724-8276 |
Satellite Healthcare South Laredo Location: 910 Guadalupe St Suite B, Laredo, Texas, 78040 Phone: (956) 729-7411 |
Us Renal Care Laredo Dialysis Location: 6801 Mcpherson Road, Laredo, Texas, 78041 Phone: (956) 725-1202 |
Satellite Healthcare Southeast Laredo Location: 4151 Jaime Zapata Memorial Hwy, Laredo, Texas, 78046 Phone: (956) 791-8100 |
Us Renal Care Laredo South Dialysis Location: 4602 Bencha Road, Laredo, Texas, 78041 Phone: (956) 753-2121 |
News Archive
At the moment, doctors rely on biopsy analysis to determine the progression of eye cancer. However, researchers now believe that a new technology, bioluminescence imaging (BLI), will allow doctors to detect tumors earlier and quickly choose a method of treatment that doesn't necessarily involve eye surgery.
Labopharm Inc. today announced the closing of its previously announced underwritten public offering of 11,764,706 units. The units were sold at a price of US$1.70 per unit for gross proceeds of US$20 million. Net proceeds were US$18,150,000 after deducting underwriting discounts and commissions, and estimated offering expenses.
One of the fundamental traits of a tumor - how it avoids the immune system - might become its greatest vulnerability, according to researchers from the University of Southern California. Their findings, demonstrated in human breast and colorectal cancers, indicate that a technique for determining a tumor's "immune signature," could be useful for diagnosing and treating specific cancers.
The Pan American Health Organization (PAHO) and the University of Geneva have signed an agreement to increase and facilitate cooperation on emergency preparedness and disaster relief programs.
Want to know how healthy your heart is? Now there's an app for that. In a proof-of-concept clinical trial, engineers at Caltech, Huntington Medical Research Institute, and USC have demonstrated that the camera on your smartphone can noninvasively provide detailed information about your heart's health.
› Verified 8 days ago